EGFR and non-small cell lung carcinoma: Thus, efficacy, cost, toxicity, and treatment compliance should be taken into account in the selection of an EGFR-TKI and treatment duration in the adjuvant therapy of completely resected EGFR-mutated NSCLC after adjuvant chemotherapy.